51.75
1.02%
0.52
시간 외 거래:
51.75
전일 마감가:
$51.23
열려 있는:
$48.91
하루 거래량:
244.52K
Relative Volume:
0.52
시가총액:
$3.54B
수익:
$38.34M
순이익/손실:
$-149.65M
주가수익비율:
-13.76
EPS:
-3.76
순현금흐름:
$-150.28M
1주 성능:
-0.33%
1개월 성능:
-0.06%
6개월 성능:
+7.01%
1년 성능:
+108.00%
Merus N V Stock (MRUS) Company Profile
명칭
Merus N V
전화
31 030 253 8800
주소
YALELAAN 62, 3584 CM UTRECHT
Merus N V Stock (MRUS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-11-02 | 개시 | Canaccord Genuity | Buy |
2023-08-21 | 개시 | TD Cowen | Outperform |
2022-08-02 | 개시 | Stifel | Buy |
2022-02-11 | 개시 | BMO Capital Markets | Outperform |
2022-02-10 | 개시 | Needham | Buy |
2021-11-17 | 재개 | Guggenheim | Buy |
2021-06-07 | 업그레이드 | Citigroup | Neutral → Buy |
2021-04-08 | 개시 | William Blair | Outperform |
2021-03-16 | 개시 | SVB Leerink | Outperform |
2020-06-26 | 개시 | H.C. Wainwright | Buy |
2020-05-27 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2019-11-20 | 재개 | Guggenheim | Buy |
2019-06-28 | 개시 | ROTH Capital | Buy |
2019-04-12 | 재개 | Guggenheim | Buy |
2019-04-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2019-03-27 | 개시 | Berenberg | Buy |
2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
2017-03-21 | 다운그레이드 | Citigroup | Buy → Neutral |
2016-12-22 | 업그레이드 | Citigroup | Neutral → Buy |
2016-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
2016-06-13 | 개시 | Citigroup | Buy |
2016-06-13 | 개시 | Guggenheim | Buy |
2016-06-13 | 개시 | Wedbush | Outperform |
모두보기
Merus N V 주식(MRUS)의 최신 뉴스
FDA extends review date for Merus' cancer drug Zeno By Investing.com - Investing.com UK
Merus (NASDAQ:MRUS) Shares Gap DownHere's Why - MarketBeat
Merus: Petosemtamab Set Up For December 2024 Data Presentation (NASDAQ:MRUS) - Seeking Alpha
US FDA extends review of Merus' gene-targeting cancer therapy - Reuters
US FDA extends review of Merus’ gene-targeting cancer therapy - PharmaLive
Merus stock slips as FDA delays drug review (MRUS:NASDAQ) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno - Investing.com
Merus Receives FDA extension of PDUFA for zenocutuzumab - GlobeNewswire
Harbor Capital Advisors Inc. Makes New Investment in Merus (NASDAQ:MRUS) - MarketBeat
abrdn plc Acquires Shares of 87,215 Merus (NASDAQ:MRUS) - MarketBeat
Merus sees cash runway into 2028 - MSN
Merus reports Q3 EPS ($1.46), consensus (88c) - MSN
Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.
Merus (NASDAQ:MRUS) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Merus N.V. Reports Q3 2024 Financial Results - TipRanks
Merus falls after updated data for lung cancer therapy - MSN
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - GlobeNewswire
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Novo Holdings A S Increases Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Coverage Initiated at UBS Group - Defense World
UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment - Investing.com India
Moody Aldrich Partners LLC Makes New Investment in Merus (NASDAQ:MRUS) - MarketBeat
UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment By Investing.com - Investing.com South Africa
Merus (NASDAQ:MRUS) Receives New Coverage from Analysts at UBS Group - MarketBeat
(MRUS) Investment Report - Stock Traders Daily
nVerses Capital LLC Acquires 1,500 Shares of Merus (NASDAQ:MRUS) - Defense World
Investing in Merus (NASDAQ:MRUS) five years ago would have delivered you a 227% gain - Yahoo Finance
Analysts Set Merus (NASDAQ:MRUS) Target Price at $82.00 - Defense World
Market Resilience: Merus N.V (MRUS) Finishes Weak at 51.35, Down -1.57 - The Dwinnex
Data Readouts At ASCO (MRUS, ORIC, CGEN, PDSB...) - RTTNews
A company insider recently sold 2,500 shares of Merus N.V [MRUS]. Should You also Consider to Sale? - Knox Daily
A History of Outperforming Analyst Forecasts and Beating the Odds: Merus N.V (MRUS) - SETE News
Merus (NASDAQ:MRUS) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
VP Controller, PAO Shuman Harry sale 2,500 shares of Merus N.V [MRUS] - Knox Daily
Market Highlights: Merus N.V (MRUS) Ends on a Low Note at 52.09 - The Dwinnex
There is no way Merus N.V (MRUS) can keep these numbers up - SETE News
What is the investor’s view on Merus N.V (MRUS)? - US Post News
Merus N.V (MRUS) receives a Buy rating from Truist - Knox Daily
Merus (NASDAQ:MRUS) Holdings Lowered by The Manufacturers Life Insurance Company - Defense World
Millennium Management LLC Has $14.39 Million Stock Position in Merus (NASDAQ:MRUS) - MarketBeat
Prepare Yourself for Liftoff: Merus N.V (MRUS) - SETE News
Guggenheim Raises Merus (NASDAQ:MRUS) Price Target to $111.00 - MarketBeat
Checking in on Merus N.V (MRUS) after recent insiders movement - Knox Daily
Merus (NASDAQ:MRUS) Price Target Raised to $111.00 at Guggenheim - Defense World
Merus NV: Driving Innovation in Cancer Treatment with Shares Valued at $50.33 - NasdaqNewsFeed
Merus begins phase 3 trial for head and neck cancer therapy - Investing.com Canada
Merus (NASDAQ:MRUS) Shares Up 4.7% - Defense World
Merus's SWOT analysis: bispecific antibody developer's stock shows promise - Investing.com India
BMO maintains Merus $95 target on positive trial data By Investing.com - Investing.com Canada
Merus begins phase 3 trial for head and neck cancer therapy By Investing.com - Investing.com South Africa
Merus's SWOT analysis: bispecific antibody developer's stock shows promise By Investing.com - Investing.com Australia
Merus N V (MRUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Merus N V 주식 (MRUS) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Shuman Harry | VP Controller, PAO |
Aug 20 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
Silverman Peter B. | COO & GC |
Jun 27 '24 |
Option Exercise |
17.94 |
10,000 |
179,400 |
10,000 |
Silverman Peter B. | COO & GC |
Jun 27 '24 |
Sale |
60.00 |
10,000 |
600,000 |
0 |
Silverman Peter B. | COO & GC |
Jun 17 '24 |
Option Exercise |
24.36 |
62,000 |
1,510,280 |
62,000 |
Silverman Peter B. | COO & GC |
Jun 17 '24 |
Sale |
56.52 |
62,000 |
3,504,178 |
0 |
Shuman Harry | VP Controller, PAO |
Jun 12 '24 |
Sale |
57.84 |
7,300 |
422,232 |
7,002 |
Shuman Harry | VP Controller, PAO |
Jun 10 '24 |
Sale |
53.22 |
1,000 |
53,224 |
7,002 |
Shuman Harry | VP Controller, PAO |
Jun 04 '24 |
Sale |
52.89 |
6,000 |
317,354 |
7,002 |
Shuman Harry | VP Controller, PAO |
Dec 19 '23 |
Sale |
26.68 |
115 |
3,068 |
7,002 |
Silverman Peter B. | COO & GC |
Dec 15 '23 |
Sale |
25.00 |
22,386 |
559,650 |
0 |
자본화:
|
볼륨(24시간):